Welcome to this week’s Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren…
Arrowhead Pharmaceuticals has launched legal action against Ionis Pharmaceuticals, aiming to neutralize Ionis’ claim that Arrowhead’s potential rival to Tryngolza breaches a patent. Arrowhead claims that Ionis’ patent is “invalid…
FibroGen has agreed to pay $1.25 million to the Securities and Exchange Commission (SEC) to address allegations that the biopharma’s former chief medical officer manipulated data for the anemia drug…
Capsida Biotherapeutics has paused a gene therapy trial after the first patient died. The biotech, which began the phase 1/2 study in July, took the action to give it time…
LB Pharmaceuticals’ decision to break cover and go public seems to have paid off, with the company bumping up the number of shares on offer for its Nasdaq listing this…
Less than two years after breaking ground on a ballyhooed 1 billion pound sterling ($1.31 billion) R&D center and future U.K. headquarters in London, Merck & Co. is not only…
One week after warning that the U.K. is undervaluing life sciences manufacturing investments, trade organization the Association of the British Pharmaceutical Industry (ABPI) has issued another call to action for…
When MEI Pharma announced it was considering its “strategic alternatives” in the wake of a failed merger last year, the options seemed pretty mundane. But, rather than winding down the…
PMV Pharmaceuticals has reported a 43% response rate in a midphase ovarian cancer trial, putting the biotech on a track it believes will lead to a filing for FDA approval…
The Trump administration is considering putting “severe restrictions” on the increasing flow of investigational drugs from China, according to reporting by The New York Times. A draft executive order is…